Policy | July 02, 2025
India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Additional capacity broadens Grace’s fine chemical capabilities for API production
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
